Skip to main content

Table 2 Characteristics of the developing cohort patients and the validation cohort patients with brain metastases from non-small cell lung cancer

From: Survival time following resection of intracranial metastases from NSCLC-development and validation of a novel nomogram

Characteristics Developing cohort (n = 223) Validation cohort (n = 112)
N (%) p value N (%)
Gender   0.013  
 Male 144 (64.6%)   73 (65.2%)
 Female 79 (35.4%)   39 (34.8%)
Age of BM diagnosis(years)   0.311  
  < 60 134 (60.1%)   61 (54.5%)
  ≥ 60 89 (39.9%)   51 (45.5%)
KPS (%)   <0.001  
  ≥ 80 99 (44.4%)   45 (40.6%)
  < 80 124 (55.6%)   67 (59.4%)
Interval from NSCLC diagnosis to BM diagnosis   0.044  
 Synchronous 159 (71.3%)   86 (76.8%)
 Metachronous 64 (28.7%)   26 (23.2%)
Time from neural symptom onset to BM diagnosis(months)   0.759  
  ≤ 1 159 (71.3%)   81 (72.3%)
 1–3 45 (20.2%)   25 (22.3%)
  > 3 19 (8.5%)   6 (5.4%)
ECM when BM diagnosis   0.009  
 Yes 85 (38.1%)   35 (31.3%)
 No 138 (61.9%)   77 (68.8%)
Number of BM   0.925  
 1 148 (66.3%)   70 (62.5%)
 2 11 (5.0%)   14 (12.5%)
 3 64 (28.7%)   28 (25.0%)
Tumor size(cm)   0.348  
  ≤ 2 62 (27.8%)   26 (23.2%)
  > 2 124 (55.6%)   67 (59.8%)
 Unknown 37 (16.6%)   19 (17.0%)
Histology   0.006  
 Adenocarcinoma 116 (52.2%)   75 (67.0%)
 Squamous cell lung cancer 25 (11.2)   20 (17.9%)
 Poorly differentiated carcinoma or histology can’t be distinguished 82 (36.8%)   17 (15.1%)
  1. BM brain metastases, KPS Karnofsky performance status, ECM extracranial metastases